InsiderSignalSign in

← Insider buys

HALO

Halozyme Therapeutics, Inc. · Healthcare

Insiders sold $37.8M of Halozyme Therapeutics, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$37.8MSold, 12 mo

$14.3BMarket cap

HALO over the last year

No insider buys filed in this year

HALO after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Congress

Members reported 5 trades in HALO since 2023.

Every filing

111 insider filings since 2018, newest first

Helen Torley · President and CEO

$6.6M−7.2%Oct 8

Matthew L. Posard · Director

$568K−8.9%Oct 2

Matthew L. Posard · Director

$2.0M−24.4%Sep 17

Helen Torley · President and CEO

$6.4M−7.2%Sep 11

Bernadette Connaughton · Director

$167K−3.9%Aug 11

Helen Torley · President and CEO

$153K−0.2%Jul 9

Bernadette Connaughton · Director

$125K−3.7%Jul 2

Mahesh Krishnan · Director

$548K−33.6%Jun 30

Helen Torley · President and CEO

$3.4M−6.1%Jun 4

Bernadette Connaughton · Director

$108K−3.6%Jun 2

Helen Torley · President and CEO

$3.4M−6.0%May 13

Bernadette Connaughton · Director

$103K−4.0%May 5

Helen Torley · President and CEO

$635K−1.0%Apr 7

Helen Torley · President and CEO

$2.6M−5.0%Apr 2

Cortney Caudill · SVP and COO

$2.0M−80.0%Mar 10

Helen Torley · President and CEO

$3.5M−6.0%Mar 4

Helen Torley · President and CEO

$3.9M−7.0%Feb 5

Bernadette Connaughton · Director

$141K−5.0%Jan 6

Cortney Caudill · SVP and COO

$278K−25.0%Dec 19

Bernadette Connaughton · Director

$59K−2.0%Dec 1

Helen Torley · President and CEO

$1.1M−2.0%Dec 1

Michael J. Labarre · SVP and Chief Technical Officer

$1.1M−10.0%Oct 16

Helen Torley · President and CEO

$1.1M−3.0%Oct 9

Helen Torley · President and CEO

$1.7M−4.0%Sep 26

Michael J. Labarre · SVP and Chief Technical Officer

$1.2M−10.0%Sep 18

Helen Torley · President and CEO

$1.8M−4.0%Sep 12

Michael J. Labarre · SVP and Chief Technical Officer

$1.2M−11.0%Aug 21

Helen Torley · President and CEO

$1.7M−4.0%Aug 15

Matthew L. Posard · Director

$1.7M−30.0%Aug 14

Michael J. Labarre · SVP and Chief Technical Officer

$1.1M−11.0%Jul 24

Nicole Labrosse · SVP and CFO

$270K−24.0%Jul 23

Nicole Labrosse · SVP and CFO

$1.6M−66.0%Jun 28

Michael J. Labarre · SVP and Chief Technical Officer

$494K−6.0%Jun 20

Matthew L. Posard · Director

$1.0M−17.0%Jun 13

Michael J. Labarre · SVP and Chief Technical Officer

$905K−11.0%May 22

Michael J. Labarre · SVP and Chief Technical Officer

$768K−11.0%Apr 17

Michael J. Labarre · SVP and Chief Technical Officer

$839K−11.0%Mar 13

Michael J. Labarre · SVP and Chief Technical Officer

$795K−11.0%Feb 28

Michael J. Labarre · SVP and Chief Technical Officer

$720K−12.0%Jan 18

Michael J. Labarre · SVP and Chief Technical Officer

$800K−12.0%Dec 13

Michael J. Labarre · SVP and Chief Technical Officer

$789K−12.0%Nov 16

Michael J. Labarre · SVP and Chief Technical Officer

$365K−6.0%Oct 17

Michael J. Labarre · SVP and Chief Technical Officer

$391K−6.0%Sep 19

Helen Torley · President and CEO

$1.3M−5.0%Aug 31

Michael J. Labarre · SVP and Chief Technical Officer

$424K−6.0%Aug 23

Helen Torley · President and CEO

$1.3M−5.0%Aug 17

James M Daly · Director

$875K−49.0%Aug 15

Helen Torley · President and CEO

$1.3M−5.0%Jul 27

Michael J. Labarre · SVP and Chief Technical Officer

$404K−6.0%Jul 19

Michael J. Labarre · SVP and Chief Technical Officer

$360K−7.0%Jun 22

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.